Prescription medicine

Sacrosidase Brand names: Sucraid

Sacrosidase (Sucraid) is a prescription medicine with an FDA approval on record since 1998. No generic is listed in FDA's NDC Directory.

No generic listed

Check it at the source: the sacrosidase FDA label on DailyMed (effective December 29, 2025, QOL Medical, LLC); the BLA 20772 record on Drugs@FDA; every sacrosidase label on DailyMed.

Highlights of the record

FDA label of December 29, 2025; NDC Directory, Drugs@FDA and Orange Book, October 8, 2026

Used for

From the label: indications and usage
Sucraid ® (sacrosidase) Oral Solution is indicated for the treatment of sucrase deficiency, which is part of congenital sucrase-isomaltase deficiency (CSID), in adult and pediatric patients 5 months of age and older.

Forms and strengths

Solution.

On the market

Earliest approval on file: April 9, 1998 Sucraid, Qol Medcl; Drugs@FDA’s file, where older or withdrawn approvals can be missing
Generic approvals: No generic approved
Labelers listed (NDC): 1 of which 0 under generic applications, 1 under brand applications, repackagers included

Supply and safety

Pharmacy cost (NADAC): Not in the survey
Shortage (FDA): No current entry
Recalls by its makers (FDA): No recall recorded
FAERS reports: 168 through July 30, 2026

What is sacrosidase used for?

From the label: indications and usage
Sucraid ® (sacrosidase) Oral Solution is indicated for the treatment of sucrase deficiency, which is part of congenital sucrase-isomaltase deficiency (CSID), in adult and pediatric patients 5 months of age and older.

FDA pharmacologic class: Sucrose-specific Enzyme.

Source: FDA drug label (Sucraid), BLA020772 (Qol Medcl), as published by QOL Medical, LLC, effective December 29, 2025 (SPL set d613bb7f-c3f4-462e-81a2-da2347cc4b6b), via openFDA; the full label on DailyMed

Is there a generic for sacrosidase (Sucraid)?

No generic sacrosidase is approved (Drugs@FDA, October 8, 2026).

1998 earliest approval on file

Source: Drugs@FDA, FDA NDC Directory and the Orange Book (openFDA bulk files, October 8, 2026)

What do FAERS reports show for sacrosidase?

The FDA Adverse Event Reporting System holds 168 reports that list sacrosidase among the medicines taken, through July 30, 2026, each a report of something that happened, not proof the medicine caused it; 0 are coded as a death and 14 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is.

The most reported reactions

Diarrhoea (named in the label)31
Abdominal Pain (named in the label)30
Nausea (named in the label)18
Abdominal Distension14
Drug Ineffective (a use or a product term, not a reaction)14
Flatulence14
Headache (named in the label)12
Product Quality Issue (a use or a product term, not a reaction)12

Side effects: the label's list and every FAERS reaction

Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026

What next?

Sacrosidase side effects: the label's list beside FAERS reports
Check an interaction: what two or more labels say about each other